Bangla News

Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy

2017-09-10

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 10, 2017 — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, today announced final results from the dose-selection phase of an ongoing Phase 1/2 trial investigating IMO-2125, Idera’s intratumorally-delivered Toll-like Receptor (TLR) 9 agonist, in combination with ipilimumab (Yervoy®), manufactured by Bristol-Myers Squibb. These data were presented at the 2017 European Society for Medical Oncology Congress (ESMO) in Madrid, Spain.    The IMO-2125-ipilimumab dose-selection phase included 18 patients, all but one of whom had progressed on nivolumab or pembrolizumab.  Patients were treated with up to 6 doses of intratumoral IMO-2125 at doses ranging from 4 to 32 mg, along with standard dosing of ipilimumab.  No dose-limiting toxicities were seen and the maximum tolerated dose (MTD) was not reached. ...

7-Eleven Donating $150,000 and Free Water to Hurricane Irma Victims

2017-09-09

In addition, 7-Eleven is encouraging customers to support the American Red Cross Hurricane Irma relief efforts. Customers can add $1.00 to their in-store purchase at participating 7-Eleven® stores nationwide or donate online at . “Our thoughts and prayers are with everyone who has been or who may soon be affected by Hurricane Irma, including our 7-Eleven employees and customers,” said Chris Tanco, Chief Operating Officer. “We encourage all who can to support them by donating money or volunteering time to relief efforts.” “Financial support from 7-Eleven helps us deliver disaster relief services and provide food, shelter, emotional support and other essential assistance,” said Don Herring, American Red Cross chief development officer. “These funds are essential to our ability to assist disaster survivors and support the first responders and volunteers who work tirelessly at the scene of a disaster.” 7-Eleven provided similar support in the aftermath...

ARMO BioSciences’s Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC

2017-09-09

“As we continue to treat and follow up patients for longer durations in the Phase 1/1b clinical trial of our immunotherapy AM0010, we remain very encouraged by the response rates, survival observations, and safety profile that we observe in patients with different types of advanced cancer,” said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences.  “Our Phase 1/1b study of AM0010 has enrolled more than 350 advanced cancer patients and we are pleased to present updates at ESMO 2017.  In patients with advanced pancreatic cancer, AM0010 in combination with FOLFOX has demonstrated promising efficacy and safety data to date, with a median overall survival of 10.2 months and one year survival rate of 43% after a median follow-up time of 17.6 months (range 11.3-21.3 months).  In advanced NSCLC and metastatic RCC, the combination of AM0010 with either nivolumab or pembrolizumab induced high response rates and durable objective responses. It is particularly...

San Diego Pain Consultants is Pleased to Welcome New Pain Physicians

2017-09-09

Introducing Dr. Brittany Grovey and Dr. Gemayel Lee Poway, CA, September 09, 2017 –()– Dr. Brittany Grovey is a fellowship-trained interventional pain provider. As a former All-Ivy, two-time Division I All-American, and professional track & field athlete competing in the 2008 Olympic Trials, Dr. Grovey aims to optimize her patients’ physical and mental well-being to help them reach their maximum potential. Dr. Grovey graduated with a degree in Biology from Brown University, and received her medical degree from the University of California, San Francisco. She went on to complete an internal medicine internship at Alameda County Medical Center in Oakland, CA, and an anesthesiology residency at the UC San Diego. Within the sub-specialties of anesthesiology, Dr. Grovey was drawn to the field of chronic pain medicine and completed pain medicine fellowship at the UC San Diego. Her particular areas of interest include sports related injuries, regenerative medicine,...

JEGroup Teaches How to Sell Your Goods and Services Globally at Barnes and Noble

2017-09-09

Business owner, Vernita Naylor, Jabez Enterprise Group (JEGroup) and Published Author, will be hosted by Barnes and Noble (Emeryville), for a book signing on Friday, October 20. B.E.S.T. Publishing’s latest book, Get the Cheese, Avoid the Traps: An Interactive Guide to Government Contracting will educate business owners on the best practices for becoming a part of the diversity and inclusion conversation by selling their goods and services to buying agencies while growing their business. Emeryville, CA, September 09, 2017 –()– Learn what it takes to become a part of the diversity and inclusion conversation at Barnes and Noble with Washington, D.C. Small Business Ambassador; Published Author and Bay Area Owner, Vernita Naylor, Jabez Enterprise Group (JEGroup). As a certified supplier in partnership with Fortune 500 and government buying agencies through the supplier diversity and government contracting programs, business owners can sell their goods and services. B.E.S.T....

U-Haul Extends 30 Days Free Self-Storage Offer to Georgia as Hurricane Irma Looms

2017-09-09

“This storm is a monster and some forecasts predict a direct hit on Atlanta,” U-Haul Company of Central Georgia president Jason Petty said. “U-Haul is a member of these communities and it is important for us to help. One way we can do that is by offering 30 days of free self-storage to our Georgia neighbors who may be affected by this hurricane.” U-Haul Companies of Atlanta North, Atlanta West, Central Georgia, Georgia Northeast, Southern Georgia and Western Georgia have made 21 facilities across 15 cities available to help. Georgians seeking assistance or needing more information about the 30 days free self-storage disaster relief should contact the nearest participating facility (locations alphabetized by city): 2885 Clairmont Road NE Atlanta, GA 30329 (404) 315-0681 2866 Forrest Hills Drive SW Atlanta, GA 30315 (404) 768-0781 300 Peters St. SW Atlanta, GA 30313 (404) 681-0502...

Equifax (EFX) Alert: Johnson Fistel Announces Filing of Class Action Lawsuit Against Equifax, Inc.; Encourages Investors to Contact the Firm for Information

2017-09-09

After the close of trading on September 7, 2017, Equifax disclosed that its databases had been breached between May and June 2017, that hackers had gained access to Company data that potentially compromised sensitive information for 143 million American consumers, including Social Security numbers, credit card numbers and driver’s license numbers.  Equifax discovered the breach on July 29, 2017, but had waited until after the close of trading nearly six weeks later to disclose the breach to consumers and Equifax’s investors.  Regulatory filings show on August 3, 2017, just days after the July 29 breach discovery, Chief Financial Officer John Gamble sold shares worth $946,374 and Joseph Loughran, president of U.S. information solutions, exercised options to dispose of stock worth $584,099. If you are an Equifax shareholder and are interested in learning more about your legal rights and remedies, please contact Jim Baker ) at . If...

NexGen Networks Highlights Importance of Carrier Diversity Amidst Accelerating Telecommunications Industry Consolidation

2017-09-08

NexGen Networks Highlights Importance of Carrier Diversity Amidst Accelerating Telecommunications Industry Consolidation NexGen offers an alternative as redundancy and carrier diversity planning is disrupted by a surge of mergers and acquisitions in the telecommunications industry. New York, NY, September 08, 2017 –()– Modern financial services and enterprises cannot afford to have key applications and services unavailable because a network carrier’s system is down. As news emerges daily of Telecom mergers and acquisitions, presenting consumers with fewer choices, true carrier diversity becomes increasingly difficult to achieve. In the aftermath of a merger, enterprises that have implemented carrier diversity may find themselves in a situation where their two physical networks become integrated and are no longer diverse. In order to preserve true carrier diversity with the associated stability and reliability it offers, enterprises now need to consider...

Global Gynecology Partnering Report 2010-2017: Deal Trends, Players and Financials

2017-09-08

Global Gynecology Partnering 2010-2017: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals. The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The...

LumaCyte joins The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

2017-09-08

CHARLOTTESVILLE, Va., Sept. 8, 2017 — LumaCyte, a Charlottesville, VA based biotechnology company, has joined NIIMBL, a Manufacturing USA institute sponsored by the National Institute of Standards and Technology (NIST). NIIMBL’s mission is to accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness. LumaCyte’s Laser Force Cytology (LFC) technology is ideally suited to help fulfill this mission by providing biopharmaceutical companies a rapid, automated cell based assay that delivers significant improvements in speed, accuracy and sensitivity. “We are incredibly excited to be an early member of NIIMBL and believe strongly in their mission to drive innovation and greater efficiency across the advanced biomanufacturing sector in the US. With our innovative,...

First container

Second container